Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Scottsdale Healthcare Is West's Only Clinical Research Site For "Dream Team" Pancreatic Cancer Research Studies
Scottsdale Healthcare, through its strategic alliance with the Translational Genomics Research Institute (TGen), is one of three clinical research sites in the United States that will participate in a three-year investigation into new approaches to treating pancreatic cancer, the fourth leading cause of cancer death in the U.S.
generic viagra online
Save Sight Now To Reduce Costs Later
Eye disease and sight loss cost the UK nearly ÷£6.5bn in 2008, according to new research** which informs, "Cost Oversight", a report due later this summer from the Royal National Institute of Blind People (RNIB). In addition, research found that the impact on quality of life (including loss of healthy life and premature death) associated with partial sight and blindness also has a cost to society, estimated at a further ÷£15.5bn in 2008.
plastic surgery before after
News of the day
U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial In Trauma Patients Remains On FDA Hold
Biopure Corporation (Nasdaq: BPUR) announced that the Food and Drug Administration has advised the U.S. Naval Medical Research Center (NMRC) by letter that it may not initiate a clinical trial of Biopure"s oxygen therapeutic Hemopure(R) [hemoglobin glutamer -- 250 (bovine)] under a proposed protocol submitted to the FDA in March 2009. As previously announced, the study, "Restore Effective Survival in Shock" (RESUS) was first proposed and submitted to the FDA in 2005. The proposed trial was placed on clinical hold at that time. It has been resubmitted repeatedly in response to FDA comments and to address comments made by the FDA Blood Products Advisory Committee at an open meeting held in December 2006. Each subsequent submission, including the most recent, was placed on clinical hold.
Sexual Health

Accumetrics, Inc. Announces 1000th Patient Enrolled In GRAVITAS Trial

Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company"s VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients. "This is a very significant milestone for Accumetrics as it brings us ever-closer to our goal of demonstrating the value of the VerifyNow System. By identifying and adjusting therapy for patients that are not responding adequately to standard doses of clopidogrel, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved outcomes. We believe that the VerifyNow System will be seen as an integral tool in ensuring that patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "We are very proud to reach this milestone, and look forward to completing enrollment soon, and sharing the results." About GRAVITAS The concept of variability in response to antiplatelet therapy has been well established. The question of whether poor response to antiplatelet therapy, as measured by a laboratory test, leads to poor outcomes is also being demonstrated with increased frequency. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company"s VerifyNow System reduces major cardiovascular adverse events post-PCI. Accumetrics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009